DAPA-HF study: Are the benefits uniform across non-diabetic subgroups

Lignende værker

• Comment on: Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine
  af: Pareek, Anil, et al.
  Udgivet: (2019)
• DAPA-HF trial signals the birth of ‘diabetic cardiology’ and more
  af: Wagdy, Kerolos, et al.
  Udgivet: (2020)
• Compelling therapy of LVH: straight (and not-so-straight) inferences from evidence
  af: Mehta, Ravi Tejraj, et al.
  Udgivet: (2019)
• Is the increase in bone mineral density after hip resurfacing uniform across the femoral neck?
  af: Kancherla, Ramprasad, et al.
  Udgivet: (2011)
• Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
  af: Docherty, Kieran F, et al.
  Udgivet: (2020)